The GYS1 Knockout 769-P Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population derived from the human 769-P renal cell carcinoma line, engineered to disrupt the glycogen synthase 1 (GYS1) gene. This pool of edited cells provides a heterogeneous loss-of-function model, enabling robust investigation of GYS1-dependent processes without clonal selection bias. The knockout model is generated through CRISPR/Cas9-mediated gene disruption, resulting in a population-level attenuation of GYS1 expression and function, suitable for studying glycogen metabolism and associated signaling pathways in a cancer-relevant epithelial context.
The host 769-P cell line is a well-established human kidney epithelial line, originally derived from a primary clear cell renal cell carcinoma. This adherent epithelial line retains key characteristics of its tumor origin, making it a valuable model for renal cancer biology, particularly studies of metabolic reprogramming and oncogenic signaling. 769-P cells exhibit typical features of clear cell renal cell carcinoma, including dysregulated hypoxia-inducible factor pathways and altered nutrient utilization, providing a relevant background for dissecting the role of glycogen metabolism in tumorigenesis.
GYS1 encodes the rate-limiting enzyme in glycogen biosynthesis, catalyzing the transfer of glucose from UDP-glucose to elongating glycogen chains. Its activity is tightly controlled by upstream regulators: insulin promotes glycogen synthesis via activation of protein phosphatase 1 (PP1) complexes containing the regulatory subunit PPP1R3C, while glycogen synthase kinase 3?? (GSK3??) phosphorylates and inactivates GYS1, inhibiting glycogen accumulation. Additional modulation is exerted by PKA and AMPK under energy stress conditions. GYS1 interacts directly with glycogenin, the primer for glycogen synthesis, and is dephosphorylated by PP1 catalytic subunit (PPP1CA) in complex with PPP1R3C, linking insulin and nutrient signals to glucose storage. Disruption of GYS1 therefore perturbs glycogen polymer formation and disturbs glucose homeostasis, impacting downstream metabolic networks.
In the 769-P renal cell carcinoma background, GYS1 knockout is particularly significant for investigating the intersection of glycogen metabolism and cancer. Clear cell renal cell carcinoma frequently exhibits aberrant glycogen accumulation, which may support survival under hypoxic and nutrient-deprived conditions. By ablating GYS1, this model permits dissection of glycogenic dependencies in tumor cells, and can be used to evaluate whether glycogen stores contribute to proliferation, stress resistance, or metastatic potential. Furthermore, since GYS1 dysfunction is implicated in glycogen storage disease type 0 and in insulin-resistant states like type 2 diabetes, the 769-P polyclonal knockout system offers a platform for comparative studies of metabolic regulation in malignant and normal epithelial contexts.
Researchers can apply this knockout product in a wide array of experimental settings, including quantitative glycogen synthesis assays using radiolabeled glucose, western blotting for phospho-GYS1 to assess upstream kinase activity, RT-qPCR for verifying transcriptional changes, and immunofluorescence for visualizing glycogen depletion. Co-immunoprecipitation studies can probe altered interactions between GYS1 and its partners such as PPP1R3C. Moreover, metabolic flux analysis and drug screening campaigns targeting glycogen-related pathways are highly feasible, owing to the robust nature of polyclonal populations. This product is ideal for those exploring cancer metabolism, diabetes mechanisms, or potential therapies for glycogen storage disorders. For more details or custom requests, please contact Ascent Research.
